Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9
Michael C. Gundry,
Lorenzo Brunetti,
Angelique Lin,
Allison E. Mayle,
Ayumi Kitano,
Dimitrios Wagner,
Joanne I. Hsu,
Kevin A. Hoegenauer,
Cliona M. Rooney,
Margaret A. Goodell,
Daisuke Nakada
Affiliations
Michael C. Gundry
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, TX 77030, USA; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
Lorenzo Brunetti
Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, TX 77030, USA; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA; Centro di Ricerca Emato-Oncologica (CREO), University of Perugia, 06156 Perugia, Italy
Angelique Lin
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Integrative Molecular and Biomedical Sciences Program, Baylor College of Medicine, Houston, TX 77030, USA
Allison E. Mayle
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, TX 77030, USA; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
Ayumi Kitano
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
Dimitrios Wagner
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA; Texas Children’s Hospital and Houston Methodist Hospital, Houston, TX 77030, USA; Institute for Medical Immunology, Charité University Medicine Berlin, 13353 Berlin, Germany
Joanne I. Hsu
Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, TX 77030, USA; Translational Biology and Molecular Medicine Program, Baylor College of Medicine, Houston, TX 77030, USA; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
Kevin A. Hoegenauer
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
Cliona M. Rooney
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA; Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA; Texas Children’s Hospital and Houston Methodist Hospital, Houston, TX 77030, USA
Margaret A. Goodell
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, TX 77030, USA; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA; Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA; Texas Children’s Hospital and Houston Methodist Hospital, Houston, TX 77030, USA; Corresponding author
Daisuke Nakada
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Stem Cells and Regenerative Medicine Center, Baylor College of Medicine, Houston, TX 77030, USA; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA; Corresponding author
Summary: Our understanding of the mechanisms that regulate hematopoietic stem/progenitor cells (HSPCs) has been advanced by the ability to genetically manipulate mice; however, germline modification is time consuming and expensive. Here, we describe fast, efficient, and cost-effective methods to directly modify the genomes of mouse and human HSPCs using the CRISPR/Cas9 system. Using plasmid and virus-free delivery of guide RNAs alone into Cas9-expressing HSPCs or Cas9-guide RNA ribonucleoprotein (RNP) complexes into wild-type cells, we have achieved extremely efficient gene disruption in primary HSPCs from mouse (>60%) and human (∼75%). These techniques enabled rapid evaluation of the functional effects of gene loss of Eed, Suz12, and DNMT3A. We also achieved homology-directed repair in primary human HSPCs (>20%). These methods will significantly expand applications for CRISPR/Cas9 technologies for studying normal and malignant hematopoiesis. : Gundry et al. develop an efficient and simple method implementing CRISPR/Cas9-mediated gene disruption and HDR in murine and human HSPCs. This method enables quick evaluation of the function of genes by performing in vitro or transplantation assays using the modified HSPCs. Keywords: HSC, hematopoietic stem cells, progenitor, human CD34, genome editing, CRISPR/Cas9, sgRNA, homology-directed repair, gene therapy, transplantation
